scholarly journals Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer

2020 ◽  
Vol 14 (1) ◽  
pp. 48-55 ◽  
Author(s):  
Mila P. Petrova ◽  
Mariyana I. Eneva ◽  
Jeliazko I. Arabadjiev ◽  
Nikolay V. Conev ◽  
Eleonora G. Dimitrova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Predictive Marker ◽  
Small Cell ◽  
Neutrophil To Lymphocyte Ratio ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
Lymphocyte Ratio

scholarly journals Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer

2018 ◽  
Vol 9 (10) ◽  
pp. 1291-1299 ◽  
Author(s):  
Takayuki Takeda ◽  
Mayumi Takeuchi ◽  
Masahiko Saitoh ◽  
Sorou Takeda
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Predictive Marker ◽  
Small Cell ◽  
Neutrophil To Lymphocyte Ratio ◽  
Small Cell Lung ◽  
Lymphocyte Ratio

scholarly journals The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer

PLoS ONE ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. e0193018 ◽  
Author(s):  
Tatsunori Kiriu ◽  
Masatsugu Yamamoto ◽  
Tatsuya Nagano ◽  
Daisuke Hazama ◽  
Reina Sekiya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Time Series ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Predictive Marker ◽  
Small Cell ◽  
Neutrophil To Lymphocyte Ratio ◽  
Small Cell Lung ◽  
Lymphocyte Ratio

scholarly journals Prognostic and Predictive Role of Neutrophil to lymphocyte Ratio in Second Line Immunotherapy of Non-small Cell Lung Cancer

2021 ◽  
Vol 6 (2) ◽  
pp. 98
Author(s):  
Chiara Bennati ◽  
Manolo D’Arcangelo ◽  
Alessio Gili ◽  
Federica Gazzaneo ◽  
Sara Pini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Neutrophil To Lymphocyte Ratio ◽  
Second Line ◽  
Small Cell Lung ◽  
Lymphocyte Ratio ◽  
Predictive Role

The utilization of pre-treatment neutrophil to lymphocyte ratio as a predictive marker for response to nivolumab therapy in non small cell lung cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e20634-e20634 ◽  
Author(s):  
Isabel Ruth Preeshagul ◽  
Kevin M. Sullivan ◽  
Doru Paul ◽  
Nagashree Seetharamu
Keyword(s):  
Lung Cancer ◽  
T Cell ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Predictive Marker ◽  
Small Cell ◽  
Neutrophil To Lymphocyte Ratio ◽  
Small Cell Lung ◽  
Lymphocyte Ratio ◽  
The Mean

e20634 Background:The tumor immune environment is integral in lung cancer progression. Cancer cells attract neutrophils through chemokine signaling pathyways into the tumor stroma. Neutrophils promote angiogenesis, metastasis and inhibit apoptosis whereas lymphocytes assist with tumor defense. Increased peritumoral neutrophil-to-lymphocyte ratio (NLR) has been shown to mediate T cell anergy and tumor immune evasion. In solid tumor pre-clinical models, elevated blood NLR correlates with increased tumor neutrophil infiltration and decreased CD3(+) T-cell infiltration. Immunotherapy is a promising anticancer strategy in Non-Small Cell Lung Cancer (NSCLC). We hypothesized that peripheral blood NLR could serve as a predictive marker for clinical benefit (CB) from this intervention. Methods:A single institution retrospective analysis of 81 patients with NSCLC treated with Nivolumab from July 2015 to November 2016. Each patient’s NLR was calculated prior to starting Nivolumab. A cut-off of 5 categorized NLR as high or low based on prior studies. The presence or absence of CB (objective response or stable disease per RECIST 1.1) after at least 3 months of therapy was determined. Descriptive statistics were utilized to summarize the data. Fischer exact test was used to compare proportions and student t test to compare means. Results:79 patients were included. 54 (68%) had low NLR and 25 (31.6%) had high NLR. 44 patients (81.48%) in the low NLR group and 7 (28%) in the high NLR group experienced CB (28%) at 3 months. This difference was statistically significant (P = 0.0001). The mean time to progression(TTP) for the low NLR population was 5.53 months, as compared to 2.39 months in the high NLR group( p = 0.0001) (95% confidence interval 1.59 to 4.55).The mean TTP in the CB cohort was 6.42 months in the low NLR group and 4.43 months in the high NLR group (p = 0.0052 ) (95% CI 0.61 to 3.39). Conclusions:The immune response to cancer is lymphocyte dependent. In our study, the majority of patients with low NLR experienced CB from Nivolumab whereas most of the patients with elevated NLR did not. NLR as a predictive biomarker should be further investigated in large prospective studies.

scholarly journals Cost-Effectiveness In The Second-Line Treatment Of Non-Small Cell Lung Cancer (Nsclc) In The Us

2015 ◽  
Vol 18 (7) ◽  
pp. A457-A458 ◽  
Author(s):  
C Graham ◽  
H Knox ◽  
LM Hess ◽  
M Jen ◽  
G Cuyun Carter ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
The Us

scholarly journals Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer

2016 ◽  
Vol Volume 9 ◽  
pp. 5761-5770 ◽  
Author(s):  
Xin Wang ◽  
Feifei Teng ◽  
Li Kong ◽  
Jinming Yu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Neutrophil To Lymphocyte Ratio ◽  
Small Cell Lung ◽  
Lymphocyte Ratio ◽  
Survival Predictor

scholarly journals Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?

2016 ◽  
Vol 23 (2) ◽  
pp. 160 ◽  
Author(s):  
K.A. Ma ◽  
G. Kasymjanova ◽  
V. Cohen ◽  
J. Agulnik
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Wild Type ◽  
Small Cell Lung

-

Sign in / Sign up

Export Citation Format

Share Document